nach oben

Erschienen in:

2016 | OriginalPaper | Buchkapitel

59. Neue Entwicklungen bei antiallergischen Therapien und Therapiekonzepten

verfasst von : M. Röcken, Prof. Dr. med., T. Biedermann, Prof. Dr. med., H. Renz, Prof. Dr. med.

Erschienen in: Allergologie

Verlag: Springer Berlin Heidelberg

Einloggen, um Zugang zu erhalten

Zusammenfassung

Das immer detailliertere Verständnis zur Pathogenese der verschiedenen Erkrankungen, die in diesem Buch abgehandelt werden, erlaubt auch die gezieltere Therapie. Eine Voraussetzung ist oftmals die Stratifizierung der Patienten. Dies bedeutet, unter der Überschrift einer Erkrankungsentität immer spezifischere Subentitäten (Endotypen) auch gezielt behandeln zu können. Die Entschlüsselung von komplexen Zusammenhängen verschiedener Erkrankungen erlauben zudem die gezielte Neutralisierung oder Blockade ganz bestimmter Moleküle und Pathways. Auch bekannte Therapieverfahren werden optimiert, nach den neuesten Erkenntnissen modifiziert und in neuen Studiendesigns analysiert. In diesem Kapitel werden neue Therapieansätze, sich im Zulassungsverfahren befindliche neue Therapien sowie Konzepte vorgestellt. Die Darstellung umfasst Urtikaria, Anaphylaxie und Mastozytose, Ansätze zur atopischen Dermatitis, Konzepte zur allergischen Rhinitis und zum Asthma sowie den letzten Stand der Entwicklung zur spezifischen Immuntherapie.

Akdis M, Akdis CA (2007) Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol 119: 780–791

Barnes N, Pavord I, Chuchalin A et al. (2012) A randomized double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma. Clin Exp Allergy 42(1): 38–48

Beck LA, Thaçi D, Hamilton JD, Graham NM, Bieber T, Rocklin R, Ming JE, Ren H, Kao R, Simpson E, Ardeleanu M, Weinstein SP, Pirozzi G, Guttman-Yassky E, Suárez-Fariñas M, Hager MD, Stahl N, Yancopoulos GD, Radin AR (2014) Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med 371: 130–139

Casale TB, Busse WW, Kline JN, Ballas ZK, Moss MH, Townley RG et al. (2006) Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol 117: 134–140

Castro M, Mathur S, Hargreave F et al. (2011) Reslizumab for poorly controlled, eosinophilic asthma. A randomized, placebo-controlled study. Am J Respir Crit Care Med 184: 1125–1132

Cavet ME, Volhejn S, Harrington KL, Zhang JZ (2013) Anti-allergic effects of mapracorat, a novel selective glucocorticoid receptor agonist, in human conjunctival fibroblasts and epithelial cells. Mol Vis 19: 1515–1525

Corren J (2013) Anti-interleukin-13 antibody therapy for asthma: one step closer. Eur Respir J 41: 255–256

Corren J, Lemaske RF, Hanania NA et al. (2011) Lebrikizumab treatment in adults with asthma. N Engl J Med 365: 1088–1098

Creticos PS, Schroeder JT, Hamilton RG, Balcer-Whaley SL, Khattignavong AP, Lindblad R et al. (2006) Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 355: 1445–1455

Darsow U, Brockow K, Pfab F, Jakob T, Petersson CJ, Borres M, Ring J, Behrendt H, Huss-Marp J (2014) Heterogeneity of molecular sensitization profiles in grass pollen allergy – implications for immunotherapy? Clin Exp Allergy 44: 778–786

Eyerich S, Eyerich K, Pennino D, Carbone T, Nasorri F, Pallotta S, Cianfarani F, Odorisio T, Traidl-Hoffmann C, Behrendt H, Durham SR, Schmidt-Weber CB, Cavani A (2009) Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J Clin Invest 119: 3573–3585

Garcia G, Magnan A, Chiron R et al. (2013) A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma. Chest 144: 411–419

Gauvreau GM, Boulet L-P, Cockcroft DW et al. (2011) Effects of Interleukin-13 blockade on allergen-induced airway responses in mild atopic asthma. Am J Resp Crit Care Med 183: 1007–1014

Ghazi A, Trikha A, Calhoun WJ (2012) Benralizumab – a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity – a novel approach for the treatment of asthma. Expert Opin Biol Ther 12: 113–118

Gueniche A, Knaudt B, Schuck E, Volz T, Bastien P, Martin R, Röcken M, Breton L, Biedermann T (2008) Effects of nonpathogenic gram-negative bacterium Vitreoscilla filiformis lysate on atopic dermatitis: a prospective, randomized, double-blind, placebo-controlled clinical study. Br J Dermatol 159(6): 1357–1363

Jutel M, Jaeger L, Suck R, Meyer H, Fiebig H, Cromwell O (2005) Allergen-specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol 116: 608–613

Jutel M, Van de Veen W, Agache I, Azkur KA, Akdis M, Akdis CA (2013) Mechanisms of allergen-specific immunotherapy and novel ways for vaccine development. Allergol Int 62: 425–433

Karamloo F, Schmid-Grendelmeier P, Kussebi F, Akdis M, Salagianni M, von Beust BR et al. (2005) Prevention of allergy by a recombinant multi-allergen vaccine with reduced IgE binding and preserved T cell epitopes. Eur J Immunol 35: 3268–3276

Kündig TM, Senti G, Schnetzler G, Wolf C, Prinz Vavricka BM, Fulurija A et al. (2006) Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults. J Allergy Clin Immunol 117: 1470–1476

Kussebi F, Karamloo F, Rhyner C, Schmid-Grendelmeier P, Salagianni M, Mannhart C et al. (2005) A major allergen gene-fusion protein for potential usage in allergen-specific immunotherapy. J Allergy Clin Immunol 115: 323–329

Larche M (2006) Immunoregulation by targeting T cells in the treatment of allergy and asthma. Curr Opin Immunol 18: 745–750

Massanari M, Nelson H, Casale T et al. (2010) Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma. J Allergy Clin Immunol 125: 383–389

Moingeon P (2012) Adjuvants for allergy vaccines. Hum Vaccin Immunother 8(10): 1492–1498

Niederberger V, Horak F, Vrtala S, Spitzauer S, Krauth MT, Valent P et al. (2004) Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acad Sci USA 101(suppl 2): 14677–14682

Niespodziana K, Focke-Tejkl M, Linhart B et al. (2011) A hypoallergenic cat vaccine based on Fel d 1-derived peptides fused to hepatitis B PreS. J Allergy Clin Immunol 127: 1562–1570

Noonan M, Korenblat P, Mosesova S et al. (2013) Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids. J Allergy Clin Immunol 132: 567–574

Oh CK, Leigh R, McLaurin KK et al. (2013) A randomized, controlled trial to evaluate the effect of an anti-interleukin-9 monoclonal antibody in adults with uncontrolled asthma. Respir Res 14: 93

Pavord ID, Korn S, Howarth P et al. (2012) Mepolizumab for severe eosinophilic asthma (DREAM): a multicenter, double-blind, placebo-controlled trial. Lancet 380: 651–659

Piper E, Brightling C, Niven R et al. (2012) A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma. Eur Resp J 41: 330–338

Pree I, Reisinger J, Focke M et al. (2007) Analysis of epitopespecificimmune responses induced by vaccination with structurally folded and unfolded recombinant Bet v 1 allergen derivatives in man. J Immunol 179: 5309–5316

Sel S, Wegmann M, Dicke T et al. (2008) Effective prevention and therapy of experimental allergic asthma using a GATA-3-specific DNAzyme. J Allergy Clin Immunol 121: 910–916

Senti G, Prinz Vavricka BM, Erdmann I et al. (2008) Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial. Proc Natl Acad Sci USA 105: 17908–17912

Senti G, von Moos S, Tay F et al. (2012a) Epicutaneous allergen-specific immunotherapy ameliorates grass pollen-induced rhinoconjunctivitis: A double-blind, placebo-controlled dose escalation study. J Allergy Clin Immunol 129: 128–35

Senti G, Crameri R, Kuster D et al. (2012b) Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections. J Allergy Clin Immunol 129: 1290–1296

Simons FE, Shikishima Y, Van Nest G, Eiden JJ, HayGlass KT (2004) Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA. J Allergy Clin Immunol 113: 1144–1151

Spertini F, Perrin Y, Audran R, Pellaton C, Boudousquié C, Barbier N, Thierry AC, Charlon V, Reymond C (2014) Safety and immunogenicity of immunotherapy with Bet v 1-derived contiguous overlapping peptides. J Allergy Clin Immunol 134: 239–240

Tanaka A, Konno M, Muto S, Kambe N, Morii E, Nakahata T, Itai A, Matsuda H (2ßß5) A novel NF-kappaB inhibitor, IMD-0354, suppresses neoplastic proliferation of human mast cells with constitutively activated c-kit receptors. Blood 105: 2324–2331

Tedeschi A, Kolkhir P, Asero R, Pogorelov D, Olisova O, Kochergin N, Cugno M (2014) Chronic urticaria and coagulation: pathophysiological and clinical aspects. Allergy 69(6): 683–691

Valenta R, Niederberger V (2007) Recombinant allergens for immunotherapy. J Allergy Clin Immunol 119: 826–830

Volz T, Skabytska Y, Guenova E, Chen KM, Frick JS, Kirschning CJ, Kaesler S, Röcken M, Biedermann T (2014) Nonpathogenic bacteria alleviating atopic dermatitis inflammation induce IL-10-producing dendritic cells and regulatory Tr1 cells. J Invest Dermatol 134(1): 96–104

Wenzel S, Wilbraham D, Fuller R et al. (2007) Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 370: 1422–1431

Wenzel S, Ford L, Pearlman D et al. (2013) Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 368(26): 2455–2466

Worm M, Lee HH, Kleine-Tebbe J et al. (2011) Development and preliminary clinical evaluation of a peptide immunotherapyvaccine for cat allergy. J Allergy Clin Immunol 127: 89–97

Zeskind B (2011) Lebrikizumab treatment in adults with asthma. N Engl J Med 365: 2432–2434

Akin C, Brockow K, D’Ambrosio C, Kirshenbaum AS, Ma Y, Longley BJ, Metcalfe DD (2003) Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Exp Hematol 31: 686–692

Akin C, Fumo G, Yavuz AS, Lipsky PE, Neckers L, Metcalfe DD (2004) A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood 103: 3222–3225

Brockow K, Grosber M, Hölzle K, Behrendt H, Ring J (2009) Neues zur Therapie der Mastozytose. Akt Dermatol 12: 491–495

Carter MC, Robyn JA, Bressler PB, Walker JC, Shapiro GG, Metcalfe DD (2007) Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis. J Allergy Clin Immunol 119: 1550–1551

Damaj G, Bernit E, Ghez D, Claisse JF, Schleinitz N, Harle JR, Canioni D, Hermine O (2008) Thalidomide in advanced mastocytosis. Br J Haematol 141: 249–253

Gleixner KV, Mayerhofer M, Sonneck K, Gruze A, Samorapoompichit P, Baumgartner C, Lee FY, Aichberger KJ, Manley PW, Fabbro D, Pickl WF, Sillaber C, Valent P (2007) Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT. Haematologica 92: 1451–1459

Gotlib J, Berube C, Growney JD, Chen CC, George TI, Williams C, Kajiguchi T, Ruan J, Lilleberg SL, Durocher JA, Lichy JH, Wang Y, Cohen PS, Arber DA, Heinrich MC, Neckers L, Galli SJ, Gilliland DG, Coutre SE (2005) Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood 106: 2865–2870

Hartmann K, Siebenhaar F, Belloni B, Brockow K, Eben R, Hartmann B, Ruëff F, Schoepke N, Staubach P, Weber A, Maurer M (2010) Effects of topical treatment with the raft modulator miltefosine and clobetasol in cutaneous mastocytosis: a randomized, double-blind, placebo-controlled trial. Br J Dermatol 162(1): 185–190

Kluin-Nelemans HC, Ferenc V, van Doormaal JJ, van Iperen C, Peters WG, Akin C, Valent P (2009) Lenalidomide therapy in systemic mastocytosis. Leuk Res 33(3): e19–22

Kontou-Fili K (2008) High omalizumab dose controls recurrent reactions to venom immunotherapy in indolent systemic mastocytosis. Allergy 63: 376–378

Nakamura R, Chakrabarti S, Akin C, Robyn J, Bahceci E, Greene A, Childs R, Dunbar CE, Metcalfe DD, Barrett AJ (2006) A pilot study of nonmyeloablative allogeneic hematopoietic stem cell transplant for advanced systemic mastocytosis. Bone Marrow Transplant 37: 353–358

Quintas-Cardama A, Kantarjian H, Verstovsek S (2007) Treatment of systemic mastocytosis with denileukin diftitox. Am J Hematol 82: 1124

Schatz M, Verhoef G, Gattermann N, Ottmann OG, Schimansky T, Alland L, Rafferty T, Gratwohl A, Follows G, Hochhaus A (2006) A phase II study of AMN107, a novel tyrosine kinase inhibitor, administered to patients (pts) with systemic mastocytosis (SM). J Clin Oncol 24: 6588 (Abstr.)

Siebenhaar F, Kuhn W, Zuberbier T, Maurer M (2007) Successful treatment of cutaneous mastocytosis and Meniere disease with anti-IgE therapy. J Allergy Clin Immunol 120: 213–215

Soriano Gomis V, Gonzalez Delgado P, Niveiro Hernandez E (2008) Failure of omalizumab treatment after recurrent systemic reactions to bee-venom immunotherapy. J Investig Allergol Clin Immunol 18: 225–226

Valent P, Akin C, Escribano L, Fodinger M, Hartmann K, Brockow K, Castells M, Sperr WR, Kluin-Nelemans HC, Hamdy NA, Lortholary O, Robyn J, van Doormaal J, Sotlar K, Hauswirth AW, Arock M, Hermine O, Hellmann A, Triggiani M, Niedoszytko M, Schwartz LB, Orfao A, Horny HP, Metcalfe DD (2007) Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 37: 435–453

Verstovsek S, Akin C, Manshouri T, Quintas-Cardama A, Huynh L, Manley P, Tefferi A, Cortes J, Giles FJ, Kantarjian H (2006) Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit. Leuk Res 30: 1365–1370

Verstovsek S, Tefferi A, Cortes J, O’Brien S, Garcia-Manero G, Pardanani A, Akin C, Faderl S, Manshouri T, Thomas D, Kantarjian H (2008) Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res 14: 3906–3915

Titel: Neue Entwicklungen bei antiallergischen Therapien und Therapiekonzepten
verfasst von: M. Röcken, Prof. Dr. med.
T. Biedermann, Prof. Dr. med.
H. Renz, Prof. Dr. med.
Verlag: Springer Berlin Heidelberg
Buch: Allergologie
Print ISBN: 978-3-642-37202-5

Electronic ISBN: 978-3-642-37203-2

Copyright-Jahr: 2016
DOI: https://doi.org/10.1007/978-3-642-37203-2_59

Neu im Fachgebiet HNO

16.04.2024 | HNO-Chirurgie | Nachrichten

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

59. Neue Entwicklungen bei antiallergischen Therapien und Therapiekonzepten

Zusammenfassung

Neu im Fachgebiet HNO

HNO-Op. auch mit über 90?

Intrakapsuläre Tonsillektomie gewinnt an Boden

Bilateraler Hörsturz hat eine schlechte Prognose

RRP: Adjuvante HPV-Impfung in jedem Alter empfehlenswert

Update HNO

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Neu im Fachgebiet HNO

HNO-Op. auch mit über 90?

Intrakapsuläre Tonsillektomie gewinnt an Boden

Bilateraler Hörsturz hat eine schlechte Prognose

RRP: Adjuvante HPV-Impfung in jedem Alter empfehlenswert

Update HNO